Angiotensin receptor blocker

Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs...


The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...


Entresto ( Sacubitril / Valsartan ), previously known as LCZ696 has been approved by Health Canada for the treatment of...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure...


The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure...


The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but...